|
GB2148299B
(en)
|
1983-09-01 |
1988-01-06 |
Hybritech Inc |
Antibody compositions of therapeutic agents having an extended serum half-life
|
|
US4908431A
(en)
|
1986-01-22 |
1990-03-13 |
Temple University-Of The Commonwealth System Of Higher Education |
Monoclonal antibodies to human kininogen and methods of preparing same
|
|
US5225539A
(en)
|
1986-03-27 |
1993-07-06 |
Medical Research Council |
Recombinant altered antibodies and methods of making altered antibodies
|
|
WO1989006692A1
(en)
|
1988-01-12 |
1989-07-27 |
Genentech, Inc. |
Method of treating tumor cells by inhibiting growth factor receptor function
|
|
US5846534A
(en)
|
1988-02-12 |
1998-12-08 |
British Technology Group Limited |
Antibodies to the antigen campath-1
|
|
AU4128089A
(en)
|
1988-09-15 |
1990-03-22 |
Rorer International (Overseas) Inc. |
Monoclonal antibodies specific to human epidermal growth factor receptor and therapeutic methods employing same
|
|
ES2052027T5
(es)
|
1988-11-11 |
2005-04-16 |
Medical Research Council |
Clonacion de secuencias de dominio variable de inmunoglobulina.
|
|
US5530101A
(en)
|
1988-12-28 |
1996-06-25 |
Protein Design Labs, Inc. |
Humanized immunoglobulins
|
|
US5859205A
(en)
|
1989-12-21 |
1999-01-12 |
Celltech Limited |
Humanised antibodies
|
|
US5976531A
(en)
|
1990-04-19 |
1999-11-02 |
The Dow Chemical Company |
Composite antibodies of human subgroup IV light chain capable of binding to tag-72
|
|
GB9022543D0
(en)
|
1990-10-17 |
1990-11-28 |
Wellcome Found |
Antibody production
|
|
US5650150A
(en)
|
1990-11-09 |
1997-07-22 |
Gillies; Stephen D. |
Recombinant antibody cytokine fusion proteins
|
|
SK281143B6
(sk)
|
1991-03-06 |
2000-12-11 |
Merck Patent Gesellschaft Mit Beschr�Nkter Haftung |
Chimérická monoklonálna protilátka, expresné vektory a farmaceutický prostriedok
|
|
ES2134212T3
(es)
|
1991-04-25 |
1999-10-01 |
Chugai Pharmaceutical Co Ltd |
Anticuerpo humano reconstituido contra el receptor de la interleuquina 6 humano.
|
|
WO1994004679A1
(en)
|
1991-06-14 |
1994-03-03 |
Genentech, Inc. |
Method for making humanized antibodies
|
|
US5565332A
(en)
|
1991-09-23 |
1996-10-15 |
Medical Research Council |
Production of chimeric antibodies - a combinatorial approach
|
|
US6042828A
(en)
|
1992-09-07 |
2000-03-28 |
Kyowa Hakko Kogyo Co., Ltd. |
Humanized antibodies to ganglioside GM2
|
|
WO1994009817A1
(en)
|
1992-11-04 |
1994-05-11 |
City Of Hope |
Novel antibody construct
|
|
US5441734A
(en)
|
1993-02-25 |
1995-08-15 |
Schering Corporation |
Metal-interferon-alpha crystals
|
|
US5840299A
(en)
|
1994-01-25 |
1998-11-24 |
Athena Neurosciences, Inc. |
Humanized antibodies against leukocyte adhesion molecule VLA-4
|
|
ES2191702T3
(es)
|
1994-03-17 |
2003-09-16 |
Merck Patent Gmbh |
Fv monocatenarios anti-egfr y anticuerpos anti-egfr.
|
|
ES2167391T3
(es)
|
1994-09-16 |
2002-05-16 |
Merck Patent Gmbh |
Inmunoconjugados ii.
|
|
US20020164788A1
(en)
|
1994-12-02 |
2002-11-07 |
The Wellcome Foundation Limited |
Humanized antibodies to CD38
|
|
DE69638269D1
(de)
|
1995-06-14 |
2010-11-18 |
Univ California |
Hochaffine humane antikörper gegen tumorantigene
|
|
ATE219517T1
(de)
|
1995-08-18 |
2002-07-15 |
Morphosys Ag |
Protein-/(poly)peptidbibliotheken
|
|
US5723125A
(en)
|
1995-12-28 |
1998-03-03 |
Tanox Biosystems, Inc. |
Hybrid with interferon-alpha and an immunoglobulin Fc linked through a non-immunogenic peptide
|
|
WO1997042329A1
(en)
|
1996-05-04 |
1997-11-13 |
Zeneca Limited |
Monoclonal antibody to cea, conjugates comprising said antibody, and their therapeutic use in an adept system
|
|
US6417337B1
(en)
|
1996-10-31 |
2002-07-09 |
The Dow Chemical Company |
High affinity humanized anti-CEA monoclonal antibodies
|
|
US6277375B1
(en)
|
1997-03-03 |
2001-08-21 |
Board Of Regents, The University Of Texas System |
Immunoglobulin-like domains with increased half-lives
|
|
US6872568B1
(en)
|
1997-03-17 |
2005-03-29 |
Human Genome Sciences, Inc. |
Death domain containing receptor 5 antibodies
|
|
GB9709421D0
(en)
|
1997-05-10 |
1997-07-02 |
Zeneca Ltd |
Chemical compounds
|
|
CN1269805A
(zh)
|
1997-07-14 |
2000-10-11 |
博尔德生物技术公司 |
生长激素和相关蛋白的衍生物
|
|
AUPP221098A0
(en)
|
1998-03-06 |
1998-04-02 |
Diatech Pty Ltd |
V-like domain binding molecules
|
|
AU3657899A
(en)
|
1998-04-20 |
1999-11-08 |
James E. Bailey |
Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity
|
|
CN100480266C
(zh)
|
1998-10-16 |
2009-04-22 |
拜奥根Idec马萨诸塞公司 |
干扰素-β融合蛋白及用途
|
|
NZ512185A
(en)
|
1998-12-09 |
2004-02-27 |
Dow Chemical Co |
A method for manufacturing glycoproteins having human- type glycosylation in plant cells
|
|
US7223397B1
(en)
|
1999-01-07 |
2007-05-29 |
Research Development Foundation |
Potentiation of anti-CD38-Immunotoxin cytotoxicity
|
|
KR100940380B1
(ko)
|
1999-01-15 |
2010-02-02 |
제넨테크, 인크. |
효과기 기능이 변화된 폴리펩티드 변이체
|
|
EP1161266A4
(en)
|
1999-03-12 |
2007-09-19 |
Univ Georgetown |
Matriptase, a serine protease and its applications
|
|
US6946129B1
(en)
|
1999-06-08 |
2005-09-20 |
Seattle Genetics, Inc. |
Recombinant anti-CD40 antibody and uses thereof
|
|
JP5179689B2
(ja)
|
2000-02-11 |
2013-04-10 |
メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング |
抗体ベース融合タンパク質の循環系内半減期の増強
|
|
US7063845B2
(en)
|
2000-04-28 |
2006-06-20 |
Gemini Science, Inc. |
Human anti-CD40 antibodies
|
|
US7521047B2
(en)
|
2000-05-12 |
2009-04-21 |
Gpc Biotech Ag |
Human polypeptides causing or leading to the killing of cells including lymphoid tumor cells
|
|
AU6541801A
(en)
|
2000-06-22 |
2002-01-02 |
Idec Pharma Corp |
Bispecific fusion protein and method of use for enhancing effector cell killing of target cells
|
|
ATE440959T1
(de)
|
2000-06-28 |
2009-09-15 |
Glycofi Inc |
Verfahren für die herstellung modifizierter glykoproteine
|
|
EP1174440A1
(en)
|
2000-07-19 |
2002-01-23 |
U-BISys B.V. |
A selectively-expressed epitope on the human CD38 molecule detected by a phage display library-derived human scFv antibody fragment
|
|
JP4336498B2
(ja)
|
2000-12-12 |
2009-09-30 |
メディミューン，エルエルシー |
延長した半減期を有する分子ならびにその組成物および用途
|
|
PA8535501A1
(es)
|
2001-01-05 |
2003-07-28 |
Pfizer |
Anticuerpos contra el receptor del factor de crecimiento similar a insulina
|
|
FR2823764B1
(fr)
|
2001-04-24 |
2003-12-12 |
Genodyssee |
Nouveaux polynucleotides et polypeptides du gene ifn alpha-17
|
|
US20020193569A1
(en)
|
2001-06-04 |
2002-12-19 |
Idec Pharmaceuticals Corporation |
Bispecific fusion protein and method of use for enhancing effector cell killing of target cells
|
|
PT1409544E
(pt)
|
2001-07-03 |
2009-09-16 |
Genentech Inc |
Anticorpos de dr4 humanos e suas utilizações
|
|
MXPA05000511A
(es)
|
2001-07-12 |
2005-09-30 |
Jefferson Foote |
Anticuepros super humanizados.
|
|
AR035119A1
(es)
|
2001-08-16 |
2004-04-14 |
Lilly Co Eli |
Anticuerpos humanos antagonistas anti-htnfsf13b
|
|
AR039067A1
(es)
|
2001-11-09 |
2005-02-09 |
Pfizer Prod Inc |
Anticuerpos para cd40
|
|
JP4562395B2
(ja)
|
2002-01-09 |
2010-10-13 |
メダレックス， インク． |
Ｃｄ３０に対するヒトモノクローナル抗体
|
|
US7317091B2
(en)
|
2002-03-01 |
2008-01-08 |
Xencor, Inc. |
Optimized Fc variants
|
|
JP4472351B2
(ja)
|
2002-03-01 |
2010-06-02 |
イミューノメディクス、インコーポレイテッド |
インターナライジング抗ｃｄ７４抗体およびその使用方法
|
|
US20040132101A1
(en)
|
2002-09-27 |
2004-07-08 |
Xencor |
Optimized Fc variants and methods for their generation
|
|
US7332585B2
(en)
|
2002-04-05 |
2008-02-19 |
The Regents Of The California University |
Bispecific single chain Fv antibody molecules and methods of use thereof
|
|
US7332580B2
(en)
|
2002-04-05 |
2008-02-19 |
The Regents Of The University Of California |
Bispecific single chain Fv antibody molecules and methods of use thereof
|
|
CA2491017A1
(en)
|
2002-07-03 |
2004-01-15 |
Immunogen, Inc. |
Antibodies to non-shed muc1 and muc16, and uses thereof
|
|
CA2498319A1
(en)
|
2002-09-09 |
2004-03-18 |
Nautilus Biotech |
Rational evolution of cytokines for higher stability, the cytokines and encoding nucleic acid molecules
|
|
WO2004022747A1
(en)
|
2002-09-09 |
2004-03-18 |
Nautilus Biotech |
Rational directed protein evolution using two-dimensional rational mutagenesis scanning
|
|
US7217797B2
(en)
|
2002-10-15 |
2007-05-15 |
Pdl Biopharma, Inc. |
Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
|
|
EP1594965A2
(en)
|
2003-02-18 |
2005-11-16 |
MERCK PATENT GmbH |
Fusion proteins of interferon alpha muteins with improved properties
|
|
US7709610B2
(en)
|
2003-05-08 |
2010-05-04 |
Facet Biotech Corporation |
Therapeutic use of anti-CS1 antibodies
|
|
WO2005044307A2
(en)
|
2003-11-04 |
2005-05-19 |
Chiron Corporation |
Methods of therapy for b cell-related cancers
|
|
AU2005235811B2
(en)
|
2004-02-06 |
2011-11-03 |
Morphosys Ag |
Anti-CD38 human antibodies and uses therefor
|
|
ES2541436T3
(es)
|
2004-02-06 |
2015-07-20 |
Morphosys Ag |
Anticuerpos humanos anti-CD38 y usos para ellos
|
|
US8034352B2
(en)
|
2005-04-06 |
2011-10-11 |
Ibc Pharmaceuticals, Inc. |
Tetrameric cytokines with improved biological activity
|
|
US7273608B2
(en)
|
2004-03-11 |
2007-09-25 |
City Of Hope |
Humanized anti-CEA T84.66 antibody and uses thereof
|
|
US7670595B2
(en)
|
2004-06-28 |
2010-03-02 |
Merck Patent Gmbh |
Fc-interferon-beta fusion proteins
|
|
JP5112863B2
(ja)
|
2004-07-01 |
2013-01-09 |
ノヴォ ノルディスク アー／エス |
ヒト抗−ｋｉｒ抗体
|
|
EP1799262A4
(en)
|
2004-10-15 |
2009-10-21 |
Seattle Genetics Inc |
ANTI-CD70 ANTIBODIES AND ITS USE FOR THE TREATMENT AND PREVENTION OF CANCER DISORDERS AND IMMUNE DISORDERS
|
|
EP3312196B1
(en)
*
|
2005-03-23 |
2019-07-17 |
Genmab A/S |
Antibodies against cd38 for treatment of multiple myeloma
|
|
EP1888647A2
(en)
|
2005-05-24 |
2008-02-20 |
MorphoSys AG |
Generation and profiling of fully human hucal gold®-derived therapeutic antibodies specific for human cd38
|
|
MX2007014889A
(es)
|
2005-05-26 |
2008-02-19 |
Schering Corp |
Fusion de interferon-inmunoglobulina g.
|
|
JP5208733B2
(ja)
|
2005-06-29 |
2013-06-12 |
イエダ リサーチ アンド デベロップメント カンパニー リミテッド |
組換えインターフェロンα２（ＩＦＮα２）変異体
|
|
DK1915398T3
(en)
|
2005-07-18 |
2016-07-04 |
Amgen Inc |
Humane anti-B7RP1 neutraliserende antistoffer
|
|
NZ566395A
(en)
|
2005-09-26 |
2012-03-30 |
Medarex Inc |
Human monoclonal antibodies to CD70
|
|
WO2007044892A2
(en)
|
2005-10-10 |
2007-04-19 |
American Diagnostica, Inc. |
Upar-binding molecule-drug conjugates and uses thereof
|
|
PL2860192T3
(pl)
|
2005-10-12 |
2018-03-30 |
Morphosys Ag |
Wytwarzanie i profilowanie w pełni ludzkich, uzyskanych z HuCAL GOLD terapeutycznych przeciwciał swoistych wobec ludzkiego CD38
|
|
WO2007053718A1
(en)
|
2005-10-31 |
2007-05-10 |
The Government Of The United States, As Represented By The Secretary Of Health And Human Services, National Institutes Of Health |
Antibodies and immunotoxins that target human glycoprotein nmb
|
|
GB0525214D0
(en)
|
2005-12-12 |
2006-01-18 |
Bioinvent Int Ab |
Biological materials and uses thereof
|
|
CN101045156B
(zh)
|
2006-03-29 |
2012-05-02 |
刘宏利 |
特异靶向性药物及其用途
|
|
EP1878747A1
(en)
|
2006-07-11 |
2008-01-16 |
greenovation Biotech GmbH |
Glyco-engineered antibodies
|
|
FR2905375A1
(fr)
|
2006-08-29 |
2008-03-07 |
Biomethodes Sa |
Variants ameliores de l'interferon alpha humain
|
|
CA2660795C
(en)
|
2006-09-18 |
2014-11-18 |
Xencor, Inc. |
Optimized antibodies that target hm1.24
|
|
AU2007302448C1
(en)
|
2006-09-26 |
2019-02-14 |
Genmab A/S |
Combination treatment of CD38-expressing tumors
|
|
EP1914242A1
(en)
*
|
2006-10-19 |
2008-04-23 |
Sanofi-Aventis |
Novel anti-CD38 antibodies for the treatment of cancer
|
|
DE102007001370A1
(de)
|
2007-01-09 |
2008-07-10 |
Curevac Gmbh |
RNA-kodierte Antikörper
|
|
US11535673B2
(en)
|
2007-04-05 |
2022-12-27 |
President and Fellows of Harvard CoHege |
Chimeric activators: quantitatively designed protein therapeutics and uses thereof
|
|
TW200902554A
(en)
|
2007-05-08 |
2009-01-16 |
Genentech Inc |
Cysteine engineered anti-MUC16 antibodies and antibody drug conjugates
|
|
EP2152751A1
(en)
|
2007-05-31 |
2010-02-17 |
Genmab A/S |
Fusion or linked proteins with extended half life
|
|
WO2009017823A2
(en)
|
2007-08-01 |
2009-02-05 |
The Government Of The United States Of America, As Represented By The Secretary, Department Of Health Of Human Services, National Institutes Of Health |
A fold-back diabody diphtheria toxin immunotoxin and methods of use
|
|
US20090076249A1
(en)
|
2007-09-19 |
2009-03-19 |
Michel De Weers |
Antibodies against CD38 for treatment of multiple myeloma
|
|
CN101868246A
(zh)
|
2007-09-21 |
2010-10-20 |
加利福尼亚大学董事会 |
被导靶的干扰素显示强的细胞凋亡和抗肿瘤活性
|
|
US20100261275A1
(en)
|
2007-12-10 |
2010-10-14 |
Yves Durocher |
Production of Recombinant Interferon Proteins
|
|
US8092804B2
(en)
|
2007-12-21 |
2012-01-10 |
Medimmune Limited |
Binding members for interleukin-4 receptor alpha (IL-4Rα)-173
|
|
HRP20140604T1
(hr)
|
2007-12-26 |
2014-09-12 |
Biotest Ag |
Sredstva koja djeluju na cd138 i njihova upotreba
|
|
US8187601B2
(en)
|
2008-07-01 |
2012-05-29 |
Aveo Pharmaceuticals, Inc. |
Fibroblast growth factor receptor 3 (FGFR3) binding proteins
|
|
MX2011009704A
(es)
|
2009-03-16 |
2011-09-28 |
Cephalon Australia Pty Ltd |
Anticuerpos humanizados con actividad anti-tumor.
|
|
EP2580243B1
(en)
|
2010-06-09 |
2019-10-16 |
Genmab A/S |
Antibodies against human cd38
|
|
US8909257B2
(en)
|
2010-06-19 |
2014-12-09 |
Qualcomm Incorporated |
Positioning protocol conveyance
|
|
NZ607473A
(en)
*
|
2010-09-27 |
2014-11-28 |
Morphosys Ag |
Anti-cd38 antibody and lenalidomide or bortezomib for the treatment of multiple myeloma and nhl
|
|
CA2824279A1
(en)
|
2010-12-22 |
2012-06-28 |
Cephalon Australia Pty Ltd |
Modified antibody with improved half-life
|
|
JOP20210044A1
(ar)
*
|
2010-12-30 |
2017-06-16 |
Takeda Pharmaceuticals Co |
الأجسام المضادة لـ cd38
|
|
WO2013059885A2
(en)
|
2011-10-28 |
2013-05-02 |
Cephalon Australia Pty Ltd |
Polypeptide constructs and uses thereof
|
|
AU2013211059B8
(en)
|
2012-01-20 |
2017-12-21 |
Centre Hospitalier Regional Universitaire De Montpellier |
Targeted mutant alpha-helical bundle cytokines
|
|
CA2866126A1
(en)
|
2012-03-03 |
2013-09-12 |
Immungene, Inc. |
Engineered antibody-interferon mutant fusion molecules
|
|
WO2014028502A1
(en)
|
2012-08-13 |
2014-02-20 |
ImmunGene Inc. |
Engineered antibody-interferon fusion molecules for treatment of autoimmune diseases
|
|
CN105051620A
(zh)
|
2013-01-25 |
2015-11-11 |
拜耳材料科技股份有限公司 |
具有体积全息图和印刷特征的安全元件
|
|
CA2909952C
(en)
|
2013-04-29 |
2021-10-12 |
Teva Pharmaceuticals Australia Pty Ltd. |
Anti-cd38 antibodies and fusions to attenuated interferon alpha-2b
|
|
US11117975B2
(en)
|
2013-04-29 |
2021-09-14 |
Teva Pharmaceuticals Australia Pty Ltd |
Anti-CD38 antibodies and fusions to attenuated interferon alpha-2B
|
|
UA119352C2
(uk)
|
2014-05-01 |
2019-06-10 |
Тева Фармасьютикалз Острейліа Пті Лтд |
Комбінація леналідоміду або помалідоміду і конструкції анти-cd38 антитіло-атенуйований інтерферон альфа-2b та спосіб лікування суб'єкта, який має cd38-експресуючу пухлину
|
|
UA125637C2
(uk)
*
|
2014-10-29 |
2022-05-11 |
Тева Фармасьютікалз Острейліа Пті Лтд |
ЗЛИТИЙ ПОЛІПЕПТИД ІНТЕРФЕРОНУ <font face="Symbol">a2</font>b
|